A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies
- 12 January 2009
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 20 (3), 513-519
- https://doi.org/10.1093/annonc/mdn655
Abstract
Background: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle. Patients and methods: Two hundred and sixty-six patients were prospectively enrolled and followed during 1053 cycles. Relevant patient informations were collected at the beginning of the first cycle and the number of days of FN were counted in the follow-up [dichotomized (no FN versus ≥1 day of FN)]. Results: Aggressive chemotherapy regimen is the major predictor of FN [odds ratio 5.2 (3.2–8.4)]. The other independent predictors are the underlying disease, an involvement of bone marrow, body surface ≤2 m2, a baseline monocyte count Conclusion: Further studies are needed to validate this score.Keywords
Funding Information
- National pour la Recherche Scientifique
This publication has 29 references indexed in Scilit:
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEuropean Journal Of Cancer, 2006
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Severe neutropenia in CHOP occurs most frequently in cycle 1: A predictive modelLeukemia & Lymphoma, 2006
- Risk Models for Predicting Chemotherapy-Induced NeutropeniaThe Oncologist, 2005
- First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation studyBreast Cancer Research, 2003
- New directions in the management of chemotherapy-induced neutropenia: Risk models, special populations, and quality of life.Seminars in Oncology, 2003
- A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapyAnnals of Oncology, 2003
- A Predictive Model for Life-Threatening Neutropenia and Febrile Neutropenia after the First Course of CHOP Chemotherapy in Patients with Aggressive Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2000
- Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trialBlood, 1992
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991